World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
46824
World Ranking
11090
National Ranking
5706

Justin F. Gainor publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Justin F. Gainor sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 638 publications — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Justin F. Gainor D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Justin F. Gainor sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 92 D-Index — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Justin F. Gainor is affiliated with Harvard University in the United States and specializes in medicine, with a focus on oncology and pulmonary and respiratory medicine. Their research portfolio includes significant contributions to cancer research, molecular biology, immunology, and related fields.

Gainor's recent publications reflect their involvement in lung cancer treatment and research. Notable papers include:

  • Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study, 2021, The Lancet Oncology
  • Lung cancer, 2021, The Lancet
  • Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer, 2020, New England Journal of Medicine
  • Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial, 2020, The Lancet Oncology
  • Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation, 2021, Cancer Discovery

These publications cover clinical trials and molecular mechanisms pertinent to lung cancer, targeting specific genetic mutations and therapeutic resistance.

The frequent coauthors collaborating with Gainor include:

  • W. Marston Linehan
  • Mark M. Awad
  • Subba R. Digumarthy
  • Mari Mino-Kenudson
  • Vivek Subbiah

Gainor's work has been predominantly published in high-impact and specialized venues such as:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Cancer Research
  • Annals of Oncology
  • Regular and Young Investigator Award Abstracts

The scientist's research is substantially grounded in the field of medicine, with 516 publications. Subfields include oncology with 231 publications, pulmonary and respiratory medicine with 184, molecular biology with 46, immunology with 35, and cancer research with 32. Specific topics frequently addressed in their studies are:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Research Studies
  • Cancer Genomics and Diagnostics
  • Lung Cancer Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • Pancreatic and Hepatic Oncology Research

This profile reflects Gainor's focused efforts on lung cancer research, particularly on targeted therapies and immunotherapy, aligning with evolving priorities in oncology and precision medicine.

Best Publications

  • Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

    Julie Brahmer;Karen L Reckamp;Paul Baas;Lucio Crinò

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

    Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

  • STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

    Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann

  • Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

    Hira Rizvi;Francisco Sanchez-Vega;Konnor La;Walid Chatila

  • Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

    Justin F. Gainor;Leila Dardaei;Satoshi Yoda;Luc Friboulet

  • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

    Alice T. Shaw;Beow Y. Yeap;Benjamin J. Solomon;Gregory J. Riely

  • EGFR Mutations and ALK Rearrangements Are Associated With Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

    Justin F. Gainor;Alice T. Shaw;Lecia V. Sequist;Xiujun Fu

  • The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer

    Luc Friboulet;Nanxin Li;Ryohei Katayama;Christian C. Lee

  • Patient-derived models of acquired resistance can identify effective drug combinations for cancer

    Adam S. Crystal;Alice T. Shaw;Lecia V. Sequist;Luc Friboulet

  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    Alexander Drilon;Geoffrey R. Oxnard;Daniel S.W. Tan;Herbert H.F. Loong

  • Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.

    Alice T Shaw;Enriqueta Felip;Todd M Bauer;Benjamin Besse;Benjamin Besse

  • ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

    Justin F. Gainor;Anna M. Varghese;Sai-Hong Ignatius Ou;Sheheryar Kabraji

  • First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

    Neal Ready;Matthew D. Hellmann;Mark M. Awad;Gregory A. Otterson

  • Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.

    Catherine A Shu;Justin F Gainor;Mark M Awad;Codruta Chiuzan

  • Resensitization to Crizotinib by the Lorlatinib Alk Resistance Mutation L1198F.

    Shaw At;Friboulet L;Leshchiner I;Gainor Jf

  • PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

    Helen Y. Zou;Luc Friboulet;David P. Kodack;Lars D. Engstrom

  • Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

    L. V. Sequist;R. S. Heist;A. T. Shaw;P. Fidias

  • Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

    Everett E. Vokes;N. Ready;E. Felip;L. Horn

  • Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

    Mark M. Awad;Ryohei Katayama;Michele McTigue;Wei Liu

  • Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer

    J. Gainor;L. Dardaei;S. Yoda;L. Friboulet

Frequent Co-Authors

Alice T. Shaw
Alice T. Shaw Harvard University
Mari Mino-Kenudson
Mari Mino-Kenudson Harvard University
Jeffrey A. Engelman
Jeffrey A. Engelman Novartis Institutes for BioMedical Research (NIBR)
Mark M. Awad
Mark M. Awad Harvard University
Lecia V. Sequist
Lecia V. Sequist Harvard University
Matthew D. Hellmann
Matthew D. Hellmann Memorial Sloan Kettering Cancer Center
Beow Y. Yeap
Beow Y. Yeap Harvard University
A. John Iafrate
A. John Iafrate Harvard University
Giuseppe Curigliano
Giuseppe Curigliano University of Milan
John V. Heymach
John V. Heymach The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA isn’t the only route to a health-focused career. Many online programs now offer flexible, accredited pathways in related fields, making advanced education more accessible to busy professionals and career changers.

For nurses aiming to advance, rn to np bridge programs provide a seamless way to move from an associate’s degree to a nurse practitioner role—all while working. Those interested in nutrition and wellness can earn an online dietitian degree, which prepares graduates for careers as registered dietitians or nutritionists.

Healthcare administrators can benefit from cahme accredited mha online programs, which are widely recognized and can unlock leadership opportunities in hospitals and clinics. Meanwhile, nurses looking to advance with minimal interruptions can consider rn to bsn no clinical hours programs, ideal for those balancing work and study.

Exploring these online options helps broaden career possibilities beyond traditional medical school, providing flexible and respected alternatives for aspiring healthcare professionals.

Best Scientists Citing Justin F. Gainor

Trending Scientists

Recently Published Articles